# Reduction of pruritus and depression using longitudinal patient-reported outcome measures in hemodialysis: a quality improvement project

**Authors:** Luis Naar, Sebastian Mussnig, Janosch Niknam, Florian Brosch, Simon Krenn, Christopher C. Mayer, Joachim Beige, Manfred Hecking

PMC · DOI: 10.1186/s41687-026-01003-6 · 2026-01-21

## TL;DR

Using repeated patient reports in hemodialysis improved detection and treatment of itching and depression, enhancing care and patient-nurse agreement.

## Contribution

A quality improvement project using PROMs in a PDAS framework to systematically address CKD-aP and depression in HD patients.

## Key findings

- 32% of patients vs. 9% of nurses reported pruritus at baseline, with improved agreement after PROMs implementation.
- Difelikefalin reduced itch severity by 3 points (p < 0.001) in 16 patients, and psychiatric referrals reduced depression scores by 4.5 points (p = 0.015).
- Patient and nurse satisfaction with assessments increased from 38% to 67% and 55% to 75%, respectively.

## Abstract

Chronic kidney disease–associated pruritus (CKD-aP) and depression are common but often underrecognized and undertreated in hemodialysis (HD) patients, lowering quality of life and worsening outcomes.

To evaluate whether the systematic, repeated collection of patient-reported outcome measures (PROMs) integrated into a Plan-Do-Act-Study (PDAS) framework could enhance recognition of CKD-aP and depression and guide treatment.

127 adult patients receiving thrice-weekly in-center HD were included. PROMs were captured electronically at predefined phases.

During Adjustment phases, individualized symptom reports were reviewed by physicians, prompting initiation of difelikefalin for CKD-aP or referral to psychiatric care for depressive symptoms.

Changes in itch (Worst-Itch Numerical Rating Scale, WI-NRS) and depression (Patient Health Questionnaire-9, PHQ-9) and concordance between patients and nurses.

At baseline, 32% of patients versus 9% of nurses reported pruritus (κ = 0.18) and 27% versus 6% reported depression (κ = 0.19). Following PROM-guided interventions, 16 patients initiated difelikefalin (median WI-NRS reduction of 3 points, p < 0.001) and five were referred for psychiatric care (median PHQ-9 reduction of 4.5 points, p = 0.015). Patient–nurse agreement improved to κ = 0.66 for pruritus and κ = 0.65 for depression at study end. Ratings of assessment adequacy rose from 38% to 67% among patients and from 55% to 75% among nurses.

Routine, repeated PROMs markedly improved recognition of CKD-aP and depression, enabled targeted therapy with meaningful relief, and strengthened patient-staff alignment. This PDAS-based strategy supports KDIGO guidance and merits broader adoption to advance patient-centered dialysis care.

The online version contains supplementary material available at 10.1186/s41687-026-01003-6.

## Linked entities

- **Chemicals:** difelikefalin (PubChem CID 24794466)
- **Diseases:** chronic kidney disease (MONDO:0005300), depression (MONDO:0002050)

## Full-text entities

- **Genes:** OPRK1 (opioid receptor kappa 1) [NCBI Gene 4986] {aka K-OR-1, KOP, KOR, KOR-1, KOR1, OPRK}
- **Diseases:** uremic (MESH:D006463), kidney failure (MESH:D051437), psychiatric (MESH:D001523), symptom (MESH:D012816), diabetic nephropathy (MESH:D003928), fatigue (MESH:D005221), heart failure (MESH:D006333), sleep disturbance (MESH:D012893), dizziness (MESH:D004244), Depression (MESH:D003866), CKD (MESH:D012080), anxiety (MESH:D001007), Kidney Disease (MESH:D007674), MH (MESH:C535694), inflammation (MESH:D007249), mood disorders (MESH:D019964), Itch (MESH:D011537), sleep disruption (MESH:D019958), pain (MESH:D010146), somnolence (MESH:D006970), Disturbance (MESH:D014832), CKD-aP (MESH:D051436)
- **Chemicals:** Gabapentinoids (-), Difelikefalin (MESH:C000657129)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12827871/full.md

---
Source: https://tomesphere.com/paper/PMC12827871